SCHEMBL6808382

SCHEMBL6808382

O=C1/C(=C/c2ccc(O)c(O)c2)Oc2c1ccc(O)c2O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 1.00
MEN1 O00255 2/20 0.64
RECQL P46063 2/20 0.64
KMT2A Q03164 2/20 0.64
KDM4E B2RXH2 1/20 0.64
PSMD14 O00487 1/20 0.64
AURKA O14965 1/20 0.64
NPC1 O15118 1/20 0.64
DAPK3 O43293 1/20 0.64
JAK2 O60674 1/20 0.64
STK17B O94768 1/20 0.64
ALPL P05186 1/20 0.64
ALPI P09923 1/20 0.64
GAA P10253 1/20 0.64
MAPT P10636 1/20 0.64
ALPG P10696 1/20 0.64
CDK4 P11802 1/20 0.64
MAOA P21397 1/20 0.64
APEX1 P27695 1/20 0.64
SYK P43405 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6611437 1.00 APP (1.00) APPMEN1RECQLKMT2AKDM4E
SCHEMBL30931489 1.00 APP (1.00) APPMEN1RECQLKMT2AKDM4E
SCHEMBL6804252 0.90 APP (0.81) APP
SCHEMBL6610772 0.90 APP (0.81) APP
SCHEMBL6809397 0.87 APP (0.76) APP
SCHEMBL6809399 0.87 APP (0.76) APP
SCHEMBL6616200 0.86 APP (0.76) APP
SCHEMBL6617139 0.86 APP (0.76) APP
SCHEMBL6809225 0.86 APP (0.76) APP
SCHEMBL6808400 0.86 APP (0.76) APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11712056-B2 Extract obtained from several plants for use in the prevention and/or treatment of chronic inflammatory bowel diseases VALBIOTIS (FR) 2023-08-01 US claimed
EP-3982924-B1 PLANT EXTRACT MIXTURE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASES VALBIOTIS (FR) 2023-07-26 EP claimed
US-20220257685-A1 PLANT EXTRACT MIXTURE FOR USE IN THE PREVENTION AND/OR TREATMENT OF CHRONIC INFLAMMATORY BOWEL DISEASES VALBIOTIS (FR) 2022-08-18 US claimed
EP-4039332-A1 METHOD OF EXTRACTION AND ENRICHMENT OF MONOGLYCOSYLATED FLAVONOIDS FROM CHRYSANTHELLUM INDICUM FOR THE TREATMENT OF INFLAMMATORY-BASED POLYARTHRITIC DISORDERS, FOR USE IN COSMETIC, NUTRACEUTICAL AND MEDICAL DEVICES AND PHARMACEUTICAL APPLICATIONS Phytoitalia SRL (IT) 2022-08-10 EP claimed
EP-3533454-B1 COMPOSITION COMPRISING A MIXTURE OF PLANT EXTRACTS OR A MIXTURE OF MOLECULES CONTAINED IN SAID PLANTS AND USE TO ACT ON THE CARBOHYDRATE AND/OR LIPID METABOLISM VALBIOTIS (FR) 2022-04-20 EP claimed
US-20040132807-A1 Aurones as telomerase inhibitors PHARMACIA ITALIA SPA (IT) 2004-07-08 US claimed
EP-4362892-B1 COMPOSITION COMPRISING AT LEAST ONE ALKYL (POLY)GLYCOSIDE, AT LEAST ONE FATTY ALCOHOL, AT LEAST ONE FATTY ACID, AND AT LEAST ONE ALKALINE AGENT OREAL (FR) 2026-04-15 EP disclosed
US-12533311-B2 Method for dyeing keratin fibres starting from isatin and from powder and/or dye extract of indigo-producing plants L'OREAL (FR) 2026-01-27 US disclosed
US-20250387309-A1 METHOD FOR THE TREATMENT OF KERATIN FIBRES COMPRISING A PRETREATMENT OR POST-TREATMENT STEP OREAL (FR) 2025-12-25 US disclosed
EP-4452203-B1 PROCESS FOR DYEING KERATIN FIBRES USING A COSMETIC COMPOSITION COMPRISING PROPANE-1,3-DIOL AND A DYEING COMPOSITION OREAL (FR) 2025-12-24 EP disclosed
US-20250375366-A1 PROCESS FOR TREATING KERATIN FIBRES USING A CARNITINE SALT OR A CARNITINE DERIVATIVE OREAL (FR) 2025-12-11 US disclosed
US-12472136-B2 Composition comprising at least one alkyl (poly)glycoside, at least one fatty alcohol, at least one fatty acid, and at least one alkaline agent L'OREAL (FR) 2025-11-18 US disclosed
US-12453686-B2 Cosmetic composition comprising at least one alkyl (poly)glycoside, N,N-dicarboxymethylglutamic acid, propane-1,3-diol, at least one fatty substance other than fatty acids, at least one dye L'OREAL (FR) 2025-10-28 US disclosed
US-20100267823-A1 AURONES AS SELECTIVE PDE INHIBITORS AND THEIR USE IN NEUROLOGICAL CONDITIONS AND DISORDERS BIOTROPICS MALAYSIA BERHAD (MY) 2010-10-21 US disclosed
US-20100267822-A1 AURONES AS ESTROGEN RECEPTOR MODULATORS AND THEIR USE IN SEX HORMONE DEPENDENT DISEASES BIOTROPICS MALAYSIA BERHAD (MY) 2010-10-21 US disclosed
US-20100267823-A1 AURONES AS SELECTIVE PDE INHIBITORS AND THEIR USE IN NEUROLOGICAL CONDITIONS AND DISORDERS BIOTROPICS MALAYSIA BERHAD (MY) 2010-10-21 US disclosed
US-20100267822-A1 AURONES AS ESTROGEN RECEPTOR MODULATORS AND THEIR USE IN SEX HORMONE DEPENDENT DISEASES BIOTROPICS MALAYSIA BERHAD (MY) 2010-10-21 US disclosed
WO-2010110647-A1 AURONES AS ESTROGEN RECEPTOR MODULATORS AND THEIR USE IN SEX HORMONE DEPENDENT DISEASES BIOTROPICS MALAYSIA BERHAD (MY) 2010-09-30 WO disclosed
WO-2010110646-A1 AURONES AS SELECTIVE PDE INHIBITORS AND THEIR USE IN NEUROLOGICAL CONDITIONS AND DISORDERS BIOTROPICS MALAYSIA BERHAD (MY) 2010-09-30 WO disclosed
US-20040132807-A1 Aurones as telomerase inhibitors PHARMACIA ITALIA SPA (IT) 2004-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375366-A1 PROCESS FOR TREATING KERATIN FIBRES USING A CARNITINE SALT OR A CARNITINE DERIVATIVE KRT18, CRAT, CKMT1A; CKMT1B APP 2493/4885MEN1 2783/4885RECQL 4394/4885
US-20100267822-A1 AURONES AS ESTROGEN RECEPTOR MODULATORS AND THEIR USE IN SEX HORMONE DEPENDENT DISEASES SHBG, GPER1, ESR2 APP 3806/4885MEN1 2779/4885RECQL 3283/4885
US-20250387309-A1 METHOD FOR THE TREATMENT OF KERATIN FIBRES COMPRISING A PRETREATMENT OR POST-TREATMENT STEP PROC, KRT18, VCL APP 3887/4885MEN1 4597/4885RECQL 4094/4885
US-20040132807-A1 Aurones as telomerase inhibitors TERT, TERF2, TERF2IP APP 3533/4885MEN1 1719/4885RECQL 426/4885
US-12533311-B2 Method for dyeing keratin fibres starting from isatin and from powder and/or dye extract of indigo-producing plants KRT18, CUTA, KRTCAP2 APP 669/4885MEN1 4820/4885RECQL 4293/4885
US-20100267823-A1 AURONES AS SELECTIVE PDE INHIBITORS AND THEIR USE IN NEUROLOGICAL CONDITIONS AND DISORDERS PDE12, PDE3A, PDE7A APP 817/4885MEN1 2855/4885RECQL 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.